Skye Bioscience, Inc. (SKYE) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-40.6%

$0.78

vs $1.32 price

Levered DCF

$1.13

After debt service

Piotroski score

1 / 9

Weak

Altman Z-score

-41.52

Distress zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-0.53×	-3.88×	-0.51×	-0.46×	-2.6×	-1.41×	16.54×	-2.74×
P/B	1.49×	1.52×	-8.94×	-2.95×	3.61×	20.47×	31.79×	-3.38×
P/S	0×	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.44×	-1.4×	-0.61×	-0.51×	-1.85×	-1.41×	7.82×	-11.1×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	3.3×	16.32×	0.84×	0.74×	2.46×	3.38×	2.05×	0.12×
Debt / equity	0.01×	0.01×	-2.16×	-0.66×	0.36×	3.32×	0.71×	-0.09×
Interest coverage	0×	-31.2×	-38.33×	-27.59×	-10.22×	-8.9×	-6.63×	-49.52×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-279.3%	-39.0%	1765.9%	647.6%	-145.3%	-1455.5%	192.0%	123.3%
Return on invested capital	-286.6%	-44.0%	-1398.7%	1785.6%	-98.1%	-322.7%	-645.6%	33.6%
Return on assets	-197.5%	-36.5%	-315.3%	-213.8%	-86.5%	-245.6%	52.7%	-980.7%
Free cash flow yield	-144.8%	-26.0%	-73.3%	-143.8%	-31.1%	-65.7%	-34.6%	-7.5%
Earnings yield	-188.0%	-25.7%	-197.5%	-219.3%	-40.3%	-71.1%	6.0%	-36.5%
Enterprise value	$24.1M	$35.3M	$22.4M	$9.6M	$14.3M	$8.3M	$16M	$52.1M
Net debt / EBITDA	0.1×	2.69×	-0.09×	-0.04×	0.89×	0.17×	-0.71×	0.1×
Cash conversion cycle (days)	-1,026	0	0	0	0	-74,359	-34,904	-3,687